van Geenen Rutger C I, Keyzer-Dekker Claudia M G, van Tienhoven Geertjan, Obertop Huug, Gouma Dirk J
Department of Surgery, Academic Medical Center, Meibergdreef 9, PO Box 22660, 1100 DD Amsterdam, The Netherlands.
World J Surg. 2002 Jun;26(6):715-20. doi: 10.1007/s00268-002-6210-2. Epub 2002 Mar 26.
In patients with unresectable peripancreatic carcinoma, pain is generally treated with pain medication or with a celiac plexus blockade. Radiotherapy has also been reported to reduce pain. The efficacy of these treatment modalities is still under discussion. The aim of this study was to analyze the effects of the various types of pain management on patients who underwent palliative bypass surgery for unresectable peripancreatic carcinoma. During the period January 1995 to December 1998 a series of 98 patients underwent palliative bypass surgery, mostly for unresectable disease found during exploration. Patients were divided into three groups: palliative bypass surgery (BP), palliative bypass surgery with an intraoperative celiac plexus blockade (CPB), and palliative bypass surgery with or without celiac plexus blockade followed by high-dose conformal radiotherapy (RT). Radiotherapy was performed only in selected patients with locally advanced disease and without metastases, implying a better prognosis of the last group. The pain medication consumption, pain medication-free survival, hospital-free survival, and overall survival were analyzed. The preoperative consumption of pain medication was significantly higher in the CPB group than in the BP or RT group. The postoperative consumption of pain medication in the CPB, BP, and RT groups increased during follow-up from 15%, 17%, and 13% before surgery to 52%, 57%, and 46%, respectively, at three-fourths of the survival time (NS). This increase in consumption of pain medication was not different in the three groups. In the RT group the median pain medication-free survival was significantly longer than in the BP or CPB group (9.3 vs. 3.1 and 3.3 months; p = 0.02). The median hospital-free survival and median overall survival were significantly longer in the RT group than in the CPB group (10.3 vs. 6.8 months, p = 0.01; and 7.1 vs. 10.8 months, p = 0.01). Celiac plexus blockade as pain management did not result in an increase of the pain medication-free survival or overall survival. Therefore a positive effect of a celiac plexus blockade on pain could not be confirmed in the present study. Radiotherapy resulted in increased pain-medication survival, hospital-free survival, and overall survival compared to celiac plexus blockade. These effects are probably partly related to patient selection.
对于无法切除的胰周癌患者,疼痛通常采用止痛药物或腹腔神经丛阻滞进行治疗。也有报道称放射治疗可减轻疼痛。这些治疗方式的疗效仍在讨论之中。本研究的目的是分析各种疼痛管理方法对因无法切除的胰周癌而接受姑息性旁路手术患者的影响。在1995年1月至1998年12月期间,98例患者接受了姑息性旁路手术,大多数是因为在探查中发现无法切除的疾病。患者被分为三组:姑息性旁路手术(BP)组、术中进行腹腔神经丛阻滞的姑息性旁路手术(CPB)组,以及进行或未进行腹腔神经丛阻滞随后接受高剂量适形放疗(RT)的姑息性旁路手术组。仅对局部晚期且无转移的选定患者进行放射治疗,这意味着最后一组患者的预后较好。分析了止痛药物的消耗量、无止痛药物生存期、无住院生存期和总生存期。CPB组术前止痛药物的消耗量显著高于BP组或RT组。CPB组、BP组和RT组术后止痛药物的消耗量在随访期间从术前的15%、17%和13%分别增加到生存时间四分之三时的52%、57%和46%(无显著性差异)。三组止痛药物消耗量的增加情况无差异。RT组无止痛药物生存期的中位数显著长于BP组或CPB组(9.3个月对3.1个月和3.3个月;p = 0.02)。RT组无住院生存期和总生存期的中位数显著长于CPB组(10.3个月对6.8个月,p = 0.01;7.1个月对10.8个月,p = 0.01)。作为疼痛管理方法的腹腔神经丛阻滞并未导致无止痛药物生存期或总生存期增加。因此,本研究中无法证实腹腔神经丛阻滞对疼痛有积极作用。与腹腔神经丛阻滞相比,放射治疗可提高无止痛药物生存期、无住院生存期和总生存期。这些效果可能部分与患者选择有关。